| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2011PLoSO...624467R |
| P356 | DOI | 10.1371/JOURNAL.PONE.0024467 |
| P932 | PMC publication ID | 3166321 |
| P698 | PubMed publication ID | 21912697 |
| P5875 | ResearchGate publication ID | 51632800 |
| P2093 | author name string | Michael Norman | |
| Geetanjali Kharmate | |||
| Ujendra Kumar | |||
| Padmesh S Rajput | |||
| Shi-He Liu | |||
| Charles F Brunicardi | |||
| Bhagavatula R Sastry | |||
| P2860 | cites work | The role of G-proteins in the dimerisation of human somatostatin receptor types 2 and 5. | Q51777226 |
| Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 Co-immunoprecipitation and fluorescence resonance energy transfer analysis. | Q51795273 | ||
| Resistance to neurotoxicity in cortical cultures from neuronal nitric oxide synthase-deficient mice | Q71483815 | ||
| Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia | Q24678573 | ||
| A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. | Q27860836 | ||
| Somatostatin and its receptor family | Q28141222 | ||
| Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus | Q28505053 | ||
| Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease | Q28513464 | ||
| Colocalization of dopamine receptor subtypes with dopamine and cAMP-regulated phosphoprotein (DARPP-32) in rat brain | Q28568771 | ||
| Developmental and regional expression in the rat brain and functional properties of four NMDA receptors | Q28570615 | ||
| Immunohistochemical expression and colocalization of somatostatin, carboxypeptidase-E and prohormone convertases 1 and 2 in rat brain | Q28578792 | ||
| Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade | Q33703262 | ||
| Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity | Q33897208 | ||
| Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders | Q34138025 | ||
| Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease | Q34185510 | ||
| Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid | Q34384772 | ||
| Mechanisms underlying NMDA receptor synaptic/extrasynaptic distribution and function | Q34629359 | ||
| Coupling of the NMDA receptor to neuroprotective and neurodestructive events | Q35012580 | ||
| Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin | Q35013054 | ||
| DARPP chocolate: a caffeinated morsel of striatal signaling | Q35044987 | ||
| Neuropeptides involved in the pathophysiology of schizophrenia and major depression | Q35130197 | ||
| The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size | Q35238524 | ||
| On the Role of Somatostatin in Seizure Control: Clues from the Hippocampus | Q35545445 | ||
| The potential of activation of somatostatinergic neurotransmission with FK960 in Alzheimer's disease | Q35609734 | ||
| Huntingtin-protein interactions and the pathogenesis of Huntington's disease | Q35704403 | ||
| Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice | Q35804816 | ||
| N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease | Q36692396 | ||
| The phosphoprotein DARPP-32 mediates cAMP-dependent potentiation of striatal N-methyl-D-aspartate responses | Q36833070 | ||
| Expression of NMDA Receptor-1 (NR1) and Huntingtin in Striatal Neurons Which Colocalize Somatostatin, Neuropeptide Y, and NADPH Diaphorase: A Double-Label Histochemical and Immunohistochemical Study | Q36870168 | ||
| Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors | Q37120419 | ||
| Impaired defense mechanism against inflammation, hyperalgesia, and airway hyperreactivity in somatostatin 4 receptor gene-deleted mice. | Q37293161 | ||
| Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease | Q37789909 | ||
| Quinolinic acid-induced increases in calbindin D28k immunoreactivity in rat striatal neurons in vivo and in vitro mimic the pattern seen in Huntington's disease | Q38298264 | ||
| C-tail mediated modulation of somatostatin receptor type-4 homo- and heterodimerizations and signaling | Q39854714 | ||
| The role of subtype-specific ligand binding and the C-tail domain in dimer formation of human somatostatin receptors | Q40537074 | ||
| Agonist-dependent dissociation of human somatostatin receptor 2 dimers: a role in receptor trafficking | Q40539553 | ||
| Calpain activation in Huntington's disease. | Q40723358 | ||
| Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization | Q40744546 | ||
| Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin | Q40958511 | ||
| Somatostatin receptor subtypes SSTR2 and SSTR5 couple negatively to an L-type Ca2+ current in the pituitary cell line AtT-20. | Q41209456 | ||
| NMDA receptor losses in putamen from patients with Huntington's disease | Q41336261 | ||
| Neurons containing NADPH-diaphorase are selectively resistant to quinolinate toxicity | Q41342466 | ||
| Glutamate receptors in the mammalian central nervous system | Q41742131 | ||
| Quinolinic acid stimulates somatostatin gene expression in cultured rat cortical neurons | Q42052839 | ||
| Neurodegeneration of somatostatin-immunoreactive neurons in HIV encephalitis | Q42436816 | ||
| Somatostatin is increased in the basal ganglia in Huntington disease | Q42449047 | ||
| Double-gene ablation of SSTR1 and SSTR5 results in hyperinsulinemia and improved glucose tolerance in mice. | Q42467071 | ||
| Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease | Q42503175 | ||
| NMDA receptor function in mouse models of Huntington disease | Q43825271 | ||
| Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease | Q44480462 | ||
| Differential changes in striatal projection neurons in R6/2 transgenic mice for Huntington's disease | Q45288683 | ||
| Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity | Q45291700 | ||
| Chronic quinolinic acid lesions in rats closely resemble Huntington's disease | Q45292667 | ||
| Striatal interneurons in Huntington's disease: selective increase in the density of calretinin-immunoreactive medium-sized neurons | Q45293336 | ||
| Calbindin D28K as a marker for the degeneration of the striatonigral pathway in Huntington's disease | Q45294692 | ||
| Selective sparing of a class of striatal neurons in Huntington's disease | Q45297134 | ||
| Increased calbindin-D28k immunoreactivity in striatal projection neurons of R6/2 Huntington's disease transgenic mice | Q45297311 | ||
| Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease | Q45299064 | ||
| Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. | Q45299435 | ||
| Striatal modulation of cAMP-response-element-binding protein (CREB) after excitotoxic lesions: implications with neuronal vulnerability in Huntington's disease. | Q45299845 | ||
| Changes in expression of N-methyl-D-aspartate receptor subunits occur early in the R6/2 mouse model of Huntington's disease | Q45301002 | ||
| Calcineurin inhibitors cause an acceleration of the neurological phenotype in a mouse transgenic for the human Huntington's disease mutation | Q45301268 | ||
| Regional Brain Concentrations of Neuropeptides in Huntington's Chorea and Schizophrenia | Q45303808 | ||
| Somatostatin is increased in the nucleus accumbens in Huntington's disease | Q45303855 | ||
| Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease. | Q45307199 | ||
| Somatostatin in medium-sized aspiny interneurons of striatum is responsible for their preservation in quinolinic acid and N-methyl-D-asparate-induced neurotoxicity | Q46592729 | ||
| Deficiency of somatostatin (SST) receptor type 5 (SSTR5) is associated with sexually dimorphic changes in the expression of SST and SST receptors in brain and pancreas. | Q47274918 | ||
| Expression of somatostatin and somatostatin receptor subtypes in Apolipoprotein D (ApoD) knockout mouse brain: An immunohistochemical analysis | Q47736458 | ||
| Colocalization of somatostatin receptor subtypes (SSTR1-5) with somatostatin, NADPH-diaphorase (NADPH-d), and tyrosine hydroxylase in the rat hypothalamus | Q48107703 | ||
| Expression of N-methyl-D-aspartate receptor subunit NR1 messenger RNA by identified striatal somatostatin cells | Q48169694 | ||
| Mice heterozygous for neurotrophin-3 display enhanced vulnerability to excitotoxicity in the striatum through increased expression of N-methyl-D-aspartate receptors | Q48380135 | ||
| Involvement of sst2 somatostatin receptor in locomotor, exploratory activity and emotional reactivity in mice. | Q48700093 | ||
| Striatal neurons containing both somatostatin- and avian pancreatic polypeptide (APP)-like immunoreactivities and NADPH-diaphorase activity: A light and electron microscopic study | Q48792880 | ||
| Expression of somatostatin receptor subtypes (SSTR1-5) in Alzheimer's disease brain: an immunohistochemical analysis | Q48850710 | ||
| Cellular expression of ionotropic glutamate receptor subunits on specific striatal neuron types and its implication for striatal vulnerability in glutamate receptor-mediated excitotoxicity | Q48955052 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Huntington's disease | Q190564 |
| knockout mouse | Q1364740 | ||
| P304 | page(s) | e24467 | |
| P577 | publication date | 2011-09-02 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Somatostatin receptor 1 and 5 double knockout mice mimic neurochemical changes of Huntington's disease transgenic mice | |
| P478 | volume | 6 |
| Q84531555 | Cell surface expression of the major amyloid-β peptide (Aβ)-degrading enzyme, neprilysin, depends on phosphorylation by mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) and dephosphorylation by protein phosphatase |
| Q82676429 | Colocalization of somatostatin receptors with DARPP-32 in cortex and striatum of rat brain |
| Q38771048 | Is Huntington's disease a tauopathy? |
| Q64269587 | Major Contribution of Somatostatin-Expressing Interneurons and Cannabinoid Receptors to Increased GABA Synaptic Activity in the Striatum of Huntington’s Disease Mice |
| Q39456064 | NMDAR hypofunction and somatostatin-expressing GABAergic interneurons and receptors: A newly identified correlation and its effects in schizophrenia |
| Q28394979 | Review: Modulation of striatal neuron activity by cyclic nucleotide signaling and phosphodiesterase inhibition |
| Q30278521 | Somatostatin 2a receptors are not expressed on functionally identified respiratory neurons in the ventral respiratory column of the rat. |
| Q38957994 | Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington's disease. |
| Q33575312 | The role of the neuropeptide somatostatin on methamphetamine and glutamate-induced neurotoxicity in the striatum of mice |
Search more.